The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.
May 15th 2024
Study results showed systemic corticosteroids induced greater remission rates alone than in combination with other immunosuppressive treatments but were linked to adverse events.
Corticosteroids Induce Remission in Patients With IgA Nephropathy, Moderate Proteinuria
January 19th 2024Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.
Clinical, Prognostic Factors Affecting Concurrent IgAN and Membranous Nephropathy Outcomes
January 15th 2024Results of the retrospective study suggested blood pressure, serum IgA, potassium, and segmental glomerulosclerosis may be predictive of the rapid progression of renal endpoints in patients with concurrent IgAN and membranous nephropathy.
Risk Factors for IgA Nephropathy Recurrence After Kidney Transplant
January 10th 2024Younger age at the time of kidney transplantation, faster progression to end-stage renal disease, a history of kidney transplantation, and no induction therapy were associated with IgAN recurrence, which was linked to poorer graft survival.
Gross Hematuria Observed in Patients with IgA Nephropathy After COVID-19 Vaccination
November 16th 2023In the new study, 71% of the patients who developed gross hematuria after a COVID-19 vaccination were females, and for 92% of the patients, the investigators observed gross hematuria had developed after the second or subsequent vaccinations.
Study Supports the Efficacy, Safety of Ravulizumab for Patients with IgA Nephropathy
November 16th 2023The ravulizumab group had a proteinuria reduction of 40.3% while the placebo group had a reduction of 10.9% by week 26, highlighting ravulizumab’s effectiveness in treating patients with IgA Nephropathy.
Phase 2b Data, Phase 3 Trial Design Provide New Insight into Atacicept in IgAN
November 4th 2023Data from multiple presentations at ASN Kidney Week 2023 offer insight into the effects of atacicept in patients with IgA nephropathy as well as the design of the phase 3 trial, which is currently enrolling.
ENVISION Trial: Sibeprenlimab Reduces 24-Hour UACR in IgA Nephropathy
November 2nd 2023Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.